Entrada Therapeutics Target Price

See Entrada Therapeutics's analyst price targets ($11) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.75

Average Target Price

$11.00

131.6% upside

1 analysts in the last 4 months

High: $11 | Low: $11

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-12	Roth Capital	$11	131.6% upside
2026-06-08	Guggenheim	$17	257.9% upside
2026-05-08	Roth Capital	$10	110.5% upside
2026-02-10	Guggenheim	$20	321.1% upside
2026-01-28	OppenheimerKostas Biliouris	$21	342.1% upside
2025-11-06	Roth Capital	$13	173.7% upside
2025-02-28	Roth Capital	$23	384.2% upside
2024-11-06	H.C. WainwrightBoobalan Pachaiyappan	$20	321.1% upside
2024-06-25	H.C. WainwrightRaghuram Selvaraju	$18	278.9% upside

Entrada Therapeutics (TRDA) FAQ

Entrada Therapeutics posts a target price of $11. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $11 for TRDA means covering analysts, on average, see the stock 131.6% upside of $4.75 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for TRDA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Entrada Therapeutics's other metric pages and overview cover the third.